2. Academic Validation
  3. Synthesis and Preclinical Evaluation of an 18F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [18F]SynVesT-2

Synthesis and Preclinical Evaluation of an 18F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [18F]SynVesT-2

  • ACS Chem Neurosci. 2020 Feb 19;11(4):592-603. doi: 10.1021/acschemneuro.9b00618.
Zhengxin Cai 1,  Songye Li 1,  Wenjie Zhang 1 2,  Richard Pracitto 1,  Xiaoai Wu 1 2,  Evan Baum 1,  Sjoerd J Finnema 1,  Daniel Holden 1,  Takuya Toyonaga 1,  Shu-Fei Lin 1,  Marcel Lindemann 1,  Anupama Shirali 1,  David C Labaree 1,  Jim Ropchan 1,  Nabeel Nabulsi 1,  Richard E Carson 1,  Yiyun Huang 1
Affiliations

Affiliations

  • 1 PET Center, Department of Radiology and Biomedical Imaging , Yale University , New Haven , Connecticut 06520 , United States.
  • 2 Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine , West China Hospital, Sichuan University , Chengdu , Sichuan 610041 , China.
PMID: 31961649 DOI: 10.1021/acschemneuro.9b00618
Abstract

Synaptic vesicle glycoprotein 2A (SV2A) is a 12-pass transmembrane glycoprotein ubiquitously expressed in presynaptic vesicles. In vivo imaging of SV2A using PET has potential applications in the diagnosis and prognosis of a variety of neuropsychiatric diseases, e.g., Alzheimer's disease, Parkinson's disease, schizophrenia, multiple sclerosis, autism, epilepsy, stroke, traumatic brain injury, post-traumatic stress disorder, depression, etc. Herein, we report the synthesis and evaluation of a new 18F-labeled SV2A PET imaging probe, [18F]SynVesT-2, which possesses fast in vivo binding kinetics and high specific binding signals in non-human primate brain.

Keywords

Alzheimer’s disease; PET; Parkinson’s disease; SV2A; fluorine-18; non-human primate.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-136873
    99.96%, SV2A Radioligand